浅表性膀胱移行细胞癌粘膜下定期注射噻替哌预防复发近期疗效观察

THERAPEUTIC EFFECT OF REGULAR SUBMUCOUS INJECTION OF THIOTEPA IN PREVENTING RELAPSE OF SUPERFICIAL BLADDER CANCER

本文通过对38例浅表性膀胱移行细胞癌患者，在开放手术或经尿道膀胱肿瘤切除（Transurethralresec-tionofbladdertumor，TURBt）术后，定期用噻替哌行膀胱粘膜下注射。经近期随访观察，发现使用该药直接注射后，可明显降低肿瘤的复发率．提示短时间内局部组织中高浓度的抗癌药物，可有效地杀死残留于组织中的肿瘤细胞；且高浓度的药物刺激可促使膀胱产生无菌性炎症反应，增强局部的免疫功能，从而起到抑制肿瘤细胞再生的作用。本组无1例发生骨髓抑制、磅胱壁坏死穿孔、出血和膀胱挛缩等并发症及毒副作用．

Thirty eight cases of superficial transitional cell bladder cancer, after abdominal orTURBt operation were treated with regular submucous injections of Thiotepa. Short termfollow-up showed that relapse rate of the tumor was greatly reduced and short duration ofhigh concentration of anti-cancer drug in bladder tissue can effectively kill the residual tumorcells. The durg can stimulate aseptic inflammatory reaction in the bladder wall promote localimmunological function, and thus inhibit the regeneration of tumor cells. In this study,there was not a single case of bone-marrow depression, bladder wall perforation or necrosis,bleeding, bladder contracture complications, or other toxic effects.